Continuous infusion meropenem and ticarcillin-clavulanate in pediatric cystic fibrosis patients

Pediatric Pulmonology

Volumn 49, Issue 3, 2014, Pages 302-306

  Zobell, Jeffery T ^a,b   Ferdinand, Christina ^a   Young, David C ^c,d  

^a PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^b Intermountain Cystic Fibrosis Pediatric Center   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d Intermountain Cystic Fibrosis Adult Center   (United States)

Author keywords

antibiotics; beta lactams; Inquilinus limosus; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTICS; BETA-LACTAMS; INQUILINUS LIMOSUS; PSEUDOMONAS AERUGINOSA;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CLAVULANIC ACIDS; CYSTIC FIBROSIS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RHODOSPIRILLACEAE; THIENAMYCINS; TICARCILLIN;

EID: 84894239902     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22820     Document Type: Article

References (22)

1. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC,. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180: 802-808.
2. Van Meter DJ, Corriveau M, Ahern JW, Lahiri T,. A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis. Pediatr Pulmonol 2009; 44: 325-329.
3. Zobell JT, Young DC, Waters CD, Ampofo K, Cash J, Marshall BC, Olson J, Chatfield BA,. A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients. Pediatr Pulmonol 2011; 46: 987-990.
4. Prescott WA, Jr., National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations. J Pediatr Pharmacol Ther 2011; 16: 262-269.
5. Zobell JT, Waters CD, Young DC, Stockmann C, Ampofo K, Sherwin CM, Spigarelli, MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. Pediatr Pulmonol 2012; 47: 1147-1158.
6. Zobell JT, Waters CD, Young DC, Stockmann C, Ampofo K, Sherwin CM, Spigarelli, MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. Pediatr Pulmonol 2013; 48: 107-122.
7. Mouton JW, den Hollander JG,. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994; 38: 931-936.
8. Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JL,. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 1997; 41: 2053-2056.
9. Zobell JT, Stockmann C, Young DC, Cash J, McDowell BJ, Korgenski K, Sherwin CM, Spigarelli M, Chatfield BA, Ampofo K,. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. Clin Ther 2011; 33: 1844-1850.
10. Hubert D, Le Roux E, Lavrut T, Wallaert B, Scheid P, Manach D, Grenet D, Sermet-Gaudelus I, Ramel S, Cracowski C,. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob Agents Chemother 2009; 53: 3650-3656.
11. Hayes D, Jr., Kanga JF, Anstead MI, Kuhn RJ,. Novel approach to the eradication of Pseudomonas aeruginosa in an infant with CF after outpatient treatment failure. Pediatr Pulmonol 2008; 43: 511-513.
12. Kuzemko J, Crawford C,. Continuous infusion of ceftazidime in cystic fibrosis. Lancet 1989; 2: 385.
13. David TJ, Devlin J,. Continuous infusion of ceftazidime in cystic fibrosis. Lancet 1989; 1: 1454-1455.
14. Rappaz I, Decosterd LA, Bille J, Pilet M, Belaz N, Roulet M,. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr 2000; 159: 919-925.
15. Byl B, Baran D, Jacobs F, Herschuelz A, Thys JP,. Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients. J Antimicrob Chemother 2001; 48: 325-327.
16. Riethmueller J, Junge S, Schroeter TW, Kuemmerer K, Franke P, Ballmann M, Claass A, Broemme S, Jeschke R, Hebestreit A,. Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection 2009; 37: 418-423.
17. Vinks AA, Brimicombe RW, Heijerman HG, Bakker W,. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother 1997; 40: 125-133.
18. Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, Sorgel F,. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2010; 54: 1275-1282.
19. Alexander D,. Enhanced Beta-lactam (BL) elimination during treatment of an acute pulmonary exacerbation (AE) in cystic fibrosis (CF). Pediatr Pulmonol 2005; 40: 288.
20. Beringer PM, Kriengkauykiat J, Zhang X, Hidayat L, Liu S, Louie S, Synold T, Burckart GJ, Rao PA, Shapiro B, et al. Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis. Pharmacotherapy 2008; 28: 883-894.
21. Beringer PM, Slaughter RL,. Transporters and their impact on drug disposition. Ann Pharmacother 2005; 39: 1097-1108.
22. Corvaia L, Li SC, Ioannides-Demos LL, Bowes G, Spicer WJ, Spelman DW, Tong N, McLean AJ,. A prospective study of the effects of oral probenecid on the pharmacokinetics of intravenous ticarcillin in patients with cystic fibrosis. J Antimicrob Chemother 1992; 30: 875-878.